945 CONCORD ST., FRAMINGHAM, MA
Reports First Quarter 2026 Financial Results and Highlights
Equity Grant Approved for Interim CEO James Parslow at Xenetic Biosciences
Reports Full Year 2025 Financial Results
Other Events
Announces Adjournment of 2025 Annual Meeting
Reports Third Quarter 2025 Financial Results
Annual Report to Security Holders
Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
Q1
Amended Annual Report
FY 2025
Q3
Q2
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload